Two papers in the Journal of Medicinal Chemistry have highlighted technology developed by scientists at Heptares Therapeutics Ltd aimed at generating new leads for drugs that target the G protein-coupled receptor (GPCR) family of proteins. ---Subscribe to MedNous to access this article--- Company News Research & University News
